Shares of Outset Medical, Inc. (NASDAQ:OM – Get Free Report) have earned an average rating of “Hold” from the five analysts that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.00.
A number of equities research analysts recently weighed in on OM shares. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research note on Wednesday, June 24th. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a report on Friday, May 8th. Finally, Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a report on Saturday, April 11th.
Get Our Latest Stock Analysis on Outset Medical
Outset Medical Price Performance
Outset Medical (NASDAQ:OM – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. The company had revenue of $27.86 million for the quarter, compared to the consensus estimate of $28.90 million. Equities analysts expect that Outset Medical will post -3.82 EPS for the current year.
Insider Transactions at Outset Medical
In related news, CFO Renee Gaeta sold 17,672 shares of Outset Medical stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total transaction of $87,299.68. Following the transaction, the chief financial officer directly owned 113,753 shares of the company’s stock, valued at $561,939.82. The trade was a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 25,337 shares of company stock worth $115,660 over the last quarter. 2.50% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of OM. Los Angeles Capital Management LLC acquired a new position in Outset Medical during the fourth quarter worth about $29,000. Legal & General Group Plc acquired a new position in Outset Medical during the second quarter worth about $34,000. BNP Paribas Financial Markets grew its holdings in Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after acquiring an additional 2,034 shares during the period. Hsbc Holdings PLC purchased a new position in Outset Medical in the 4th quarter worth about $46,000. Finally, HRT Financial LP purchased a new position in Outset Medical in the 4th quarter worth about $58,000.
About Outset Medical
Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.
Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.
Read More
- Five stocks we like better than Outset Medical
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.
